Regeneron Collaborates with CytomX in Bispecific Cancer Deal
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 11 (Table of Contents)
Published: 21 Nov-2022
DOI: 10.3833/pdr.v2022.i11.2749 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Regeneron and CytomX Therapeutics have entered into a collaboration and licensing agreement, worth up to US$ 2 B, to develop next-generation bispecific immunotherapies for oncology indications...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS